1. Scrip
  2. >>Business
  3. >>Deals

BioNTech Bolsters Cancer Immunotherapy Ambitions In Pact With Cash-Poor Ryvu

 
• By Joseph Haas

Deal Snapshot: German firm gets license rights to Ryvu’s STING agonist portfolio in addition to collaborating on immunomodulators. Ryvu adds need cash via upfront and equity payments from BioNTech.

Cash infusion
Ryvu gets needed infusion of cash in tie-up with BioNTech • Source: Shutterstock

Who: BioNTech SE/Ryvu Therapeutics

What: Ryvu licenses its STING agonist portfolio to BioNTech and also inks a multi-target research collaboration to advance small molecule...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Deals

More from Business